Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 6:21 a.m.

    📋 Gossamer Bio Inc (GOSS) - Regulatory Update

    Filing Date: 2022-06-10

    Accepted: 2022-06-10 16:05:34

    Event Type: Regulatory Update

    Event Details:

    Gossamer Bio Inc (GOSS) Announces Regulatory Update Gossamer Bio Inc (GOSS) provided an update on regulatory developments for its product portfolio. Regulatory Update Details: None Clinical Development:

    🔬 Clinical Development Pipeline (Gossamer Bio Inc):

    Product Type Development Stage Therapeutic Area Source
    Placebo DRUG Phase PHASE1 Safety Issues ClinicalTrials.gov
    Generic Dry Powder Inhaler DEVICE Phase PHASE1 Safety Issues ClinicalTrials.gov
    GB002 DRUG Phase PHASE1 Safety Issues ClinicalTrials.gov
    GB004 DRUG Phase PHASE1 Ulcerative Colitis ClinicalTrials.gov
    GB001 DRUG Phase PHASE2 Asthma ClinicalTrials.gov
    pembrolizumab DRUG Phase PHASE1 Pancreatic Adenocarcinoma ClinicalTrials.gov
    nab-paclitaxel and gemcitabine DRUG Phase PHASE1 Pancreatic Adenocarcinoma ClinicalTrials.gov
    GB1275 DRUG Phase PHASE1 Pancreatic Adenocarcinoma ClinicalTrials.gov
    GB5121 DRUG Phase PHASE1 CNS Lymphoma ClinicalTrials.gov
    GB002 (seralutinib) DRUG Phase PHASE2 Pulmonary Artery Hypertension ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Gossamer Bio Inc
    • Ticker Symbol: GOSS

Search

News categories